Findings

What do systematic reviews say?

130 questions · 137 findings · 36 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 4.4%GRADE not reported 3 · 2.2%Very low 18 · 13.1%Low 55 · 40.1%Moderate 41 · 29.9%High 14 · 10.2%

Intermittent/cyclic etidronate 400 mg/day vs placebo

Serious adverse events · postmenopausal women with a higher risk for fracturesa

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa

The review found no eligible studies for this question.

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intermittent/cyclic etidronate 400 mg/day vs placebo

Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa

Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 1.07 [0.72, 1.58]
Studies not reported
Low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Hip Fracture · postmenopausal women with a higher risk for fracturesa

It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 0.93 [0.17, 5.19]
Studies not reported
Very low

Risedronate 5 mg/day vs placebo

Wrist fractures · pPostmenopausal women at higher risk of fractures1

It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.64 [0.33, 1.24]
Studies not reported
Very low

Risedronate 5 mg/day vs placebo

Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.98 [0.9, 1.07]
Studies not reported
High

Risedronate 5 mg/day vs placebo

Serious adverse events · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 1 [0.94, 1.07]
Studies not reported
Moderate

Risedronate 5 mg/day vs placebo

Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Risedronate 5 mg/day vs placebo

Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate

Risedronate 5 mg/day vs placebo

Hip Fracture · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.73 [0.56, 0.94]
Studies not reported
Low